Background/Aims: Semantic dementia (SD) is a clinical subclassification of frontotemporal lobar degeneration. Patients with ‘pure SD’ present with semantic memory impairment preceding the frontal symptoms, and there have been no reports of familial cases. Methods: We evaluated the clinical features of, and performed neuropsychological examinations on, the proband and two affected family members. Then we performed neuroimaging and genetic analysis of MAPT and other dementia-related genes in the proband. Results: All three cases had semantic memory impairment with loss of word meanings as the primary early symptom. We diagnosed all cases as pure SD and identified a P301L mutation in the MAPT gene of the proband. Conclusion: Although the P301L mutation identified here has been previously described as pathogenic for frontotemporal dementia with parkinsonism-17 (FTDP-17), the proband and his two affected relatives showed different clinical symptoms from those of typical FTDP-17 cases who carry the P301L mutation. Pathologically, pure SD usually shows a TAR DNA-binding protein proteinopathy, but the molecular understanding of SD is not well established. Although our cases were clinically pure SD, the proband has a tau gene mutation, which would lead to tauopathy. These findings suggest that reconsideration of the molecular understanding of SD is warranted.

1.
Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–1554.
2.
Snowden JS, Mann, DMA, Neary D: The frontal lobes and behaviour: Theoretical considerations; in Fronto-temporal lobar degeneration: fronto-temporal dementia, progressive aphasia, semantic dementia. Clinical Neurology and Neurosurgery Monographs 1996;147–167.
3.
The Lund and Manchester Groups: Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416–418.
4.
Hodges JR, Patterson K: Semantic dementia: A unique clinicopathological syndrome. Lancet Neurol 2007;6:1004–1014.
5.
Snowden JS: Semantic dysfunction in frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 1999;10(suppl 1):33–36.
6.
Snowden JS, Thompson JC, Neary D: Knowledge of famous faces and names in semantic dementia. Brain 2004;127:860–872.
7.
Bright P, Moss HE, Stamatakis EA, Tyler LK: Longitudinal studies of semantic dementia: The relationship between structural and functional changes over time. Neuropsychologia 2008;46:2177–2188.
8.
Chan D, Fox NC, Scahill RI, Crum WR, Whitwell JL, Leschziner G, Rossor AM, Stevens JM, Cipolotti L, Rossor MN: Patterns of temporal lobe atrophy in semantic dementia and Alzheimer’s disease. Ann Neurol 2001;49:433–442.
9.
Galton CJ, Patterson K, Graham K, Lambon-Ralph MA, Williams G, Antoun N, Sahakian BJ, Hodges JR: Differing patterns of temporal atrophy in Alzheimer’s disease and semantic dementia. Neurology 2001;57:216–225.
10.
Pickering-Brown SM, Richardson AM, Snowden JS, McDonagh AM, Burns A, Braude W, Baker M, Liu WK, Yen SH, Hardy J, Hutton M, Davies Y, Allsop D, Craufurd D, Neary D, Mann DM: Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. Brain 2002;125:732–751.
11.
Pickering-Brown SM, Rollinson S, Du Plessis D, Morrison KE, Varma A, Richardson AM, Neary D, Snowden JS, Mann DM: Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: Comparison with patients with MAPT and no known mutations. Brain 2008;131:721–731.
12.
Davies RR, Hodges JR, Kril JJ, Patterson K, Halliday GM, Xuereb JH: The pathological basis of semantic dementia. Brain 2005;128:1984–1995.
13.
Forman MS, Trojanowski JQ, Lee VM: TDP-43: a novel neurodegenerative proteinopathy. Curr Opin Neurobiol 2007;17:548–555.
14.
Snowden J, Neary D, Mann D: Frontotemporal lobar degeneration: Clinical and pathological relationships. Acta Neuropathol 2007;114:31–38.
15.
Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P, Nestor PJ, Patterson K: Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 2010;133:300–306.
16.
Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM: Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: Consensus recommendations. Acta Neuropathol 2009;117:15–18.
17.
Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM: Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010;119:1–4.
18.
Wechsler D (ed): Manual for the Wechsler Adult Intelligence Scale – Revised. New York, The Psychological Corporation, 1981.
19.
Mimura M, Kato M, Sano Y, Kojima T, Naeser M, Kashima H: Prospective and retrospective studies of recovery in aphasia. Changes in cerebral blood flow and language functions. Brain 1998;121:2083–2094.
20.
Reitan RM (ed): Trail Making Test: Manual for Administration and Scoring. Tucson, Reitan Neuropsychology Laboratory, 1992.
21.
Ichiba M, Nakamura M, Kusumoto A, Mizuno E, Kurano Y, Matsuda M, Kato M, Agemura A, Tomemori Y, Muroya S, Nakabeppu Y, Sano A: Clinical and molecular genetic assessment of a chorea-acanthocytosis pedigree. J Neurol Sci 2007;263:124–132.
22.
Fisher GM: A corrected table for determining the significance of the difference between verbal and performance IQ’s on the WAIS and the Wechsler-Bellevue. J Clin Psychol 1960;16:7–8.
23.
Waragai M, Yamada T, Matsuda H: Evaluation of brain perfusion spect using an easy z-score imaging system (EZIS) as an adjunct to early-diagnosis of neurodegenerative diseases. J Neurol Sci 2007;260:57–64.
24.
Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M: Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999;8:711–715.
25.
Chapman J, Estupinan J, Asherov A, Goldfarb LG: A simple and efficient method for apolipoprotein e genotype determination. Neurology 1996;46:1484–1485.
26.
Ghidoni R, Signorini S, Barbiero L, Sina E, Cominelli P, Villa A, Benussi L, Binetti G: The H2 MAPT haplotype is associated with familial frontotemporal dementia. Neurobiol Dis 2006;22:357–362.
27.
Hutton M: Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 2001;56:S21–S25.
28.
Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D’Amato CJ, Gilman S: Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference participants. Ann Neurol 1997;41:706–715.
29.
Heutink P, Stevens M, Rizzu P, Bakker E, Kros JM, Tibben A, Niermeijer MF, van Duijn CM, Oostra BA, van Swieten JC: Hereditary frontotemporal dementia is linked to chromosome 17q21-q22: a genetic and clinicopathological study of three dutch families. Ann Neurol 1997;41:150–159.
30.
Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P: Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702–705.
31.
Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD: Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998;43:815–825.
32.
Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B: Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 1998;95:7737–7741.
33.
Wszolek ZK, Tsuboi Y, Ghetti B, Pickering-Brown S, Baba Y, Cheshire WP: Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Orphanet J Rare Dis 2006;1:30.
34.
Arrasate M, Perez M, Armas-Portela R, Avila J: Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations. FEBS Lett 1999;446:199–202.
35.
Donker Kaat L, Boon AJ, Azmani A, Kamphorst W, Breteler MM, Anar B, Heutink P, van Swieten JC: Familial aggregation of parkinsonism in progressive supranuclear palsy. Neurology 2009;73:98–105.
36.
Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, Lees AJ, Rossor MN, Quinn NP, Kertesz A, Khan MN, Hardy J, Lantos PL, St George-Hyslop P, Munoz DG, Mann D, Lang AE, Bergeron C, Bigio EH, Litvan I, Bhatia KP, Dickson D, Wood NW, Hutton M: Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56:1702–1706.
37.
Pastor P, Ezquerra M, Tolosa E, Munoz E, Marti MJ, Valldeoriola F, Molinuevo JL, Calopa M, Oliva R: Further extension of the H1 haplotype associated with progressive supranuclear palsy. Mov Disord 2002;17:550–556.
38.
Sobrido MJ, Miller BL, Havlioglu N, Zhukareva V, Jiang Z, Nasreddine ZS, Lee VM, Chow TW, Wilhelmsen KC, Cummings JL, Wu JY, Geschwind DH: Novel tau polymorphisms, tau haplotypes, and splicing in familial and sporadic frontotemporal dementia. Arch Neurol 2003;60:698–702.
39.
Verpillat P, Camuzat A, Hannequin D, Thomas-Anterion C, Puel M, Belliard S, Dubois B, Didic M, Michel BF, Lacomblez L, Moreaud O, Sellal F, Golfier V, Campion D, Clerget-Darpoux F, Brice A: Association between the extended tau haplotype and frontotemporal dementia. Arch Neurol 2002;59:935–939.
40.
Neumann M: Molecular neuropathology of TDP-43 proteinopathies. Int J Mol Sci 2009;10:232–246.
41.
Mackenzie IR, Baborie A, Pickering-Brown S, Du Plessis D, Jaros E, Perry RH, Neary D, Snowden JS, Mann DM: Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: Classification and relation to clinical phenotype. Acta Neuropathol 2006;112:539–549.
42.
Bessi V, Bagnoli S, Nacmias B, Tedde A, Sorbi S, Bracco L: Semantic dementia associated with mutation V363I in the tau gene. J Neurol Sci 2010;296:112–114.
43.
Munoz DG, Ros R, Fatas M, Bermejo F, de Yebenes JG: Progressive nonfluent aphasia associated with a new mutation V363I in tau gene. Am J Alzheimers Dis Other Demen 2007;22:294–299.
44.
Anfossi M, Bernardi L, Gallo M, Geracitano S, Colao R, Puccio G, Curcio SAM, Frangipane F, Mirabelli M, Tomaino C, Smirne N, Maletta R, Bruni AC: MAPT V363I variation in a sporadic case of frontotemporal dementia: variable penetrant mutation or rare polymorphism? Alzheimer Dis Assoc Disord 2011;25:96–99.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.